Bayer (BAYRY) announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR) with high selectivity for mutant versus wild-type EGFR. The phase I/II SOHO-01 study evaluates the safety and pre ...